Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Truvada for Epstein-Barr Virus Replication in Multiple Sclerosis
NCT05957913Phase 2Enrolling by invitation
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in multiple sclerosis (MS), sponsored by Massachusetts General Hospital. Primary endpoint: Epstein Barr virus viral load at 3 months. Started Jun 2023; status: enrolling by invitation.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05957913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957913.